Firms ally to develop drug for cancer, autoimmune disease

05/17/2013 | Genetic Engineering & Biotechnology News

RuiYi and Genor Biopharma agreed to co-develop the former's experimental monoclonal antibody drug RYI-008 against cancer and autoimmune diseases, particularly rheumatoid arthritis, in China. The deal follows RuiYi's announcement that it would use CMC Biologics' CHEF1 high-productivity expression plasmid to speed work on a cell line for RYI-008.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC